Neuroblastoma Cancer. Malignant neoplasm of peripheral nerves and autonomic nervous system
Conditions
Interventions
Intervention 1: Intervention group: includes patients who, in addition to standard treatment, receive the optimized measles vaccine intraperitoneally in 2 doses 4 weeks apart. At the same time as bei
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 21 Years
Inclusion criteria
Inclusion criteria: Patient age 2 to 21 The patient must be considered by a pediatric oncologist to be refractory to conventional treatments or for which there is no standard treatment. The non-central nervous system solid tumor has been confirmed by a histologist. Proper functioning of liver, kidney and bone marrow The ability to understand and sign the consent form by the patient and one of these cases: the patient's spouse, parent or guardian. Complying with all protocol steps including sample submission and returning to the clinical study site for subsequent visits Absence of autoimmune diseases or diseases of the immune system
Exclusion criteria
Exclusion criteria: Life-threatening acute infection Absence of any previous record that describes the doctor's treatment and orders were nor followed by patient. Using drugs that weaken the immune system Affected by any diseases that disturbs the immune system Having any previous record of organ transplantation Allergy to measles vaccine Using other investigational treatments at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: Thermometer.;Examining changes in the patient's heart condition. Timepoint: Hourly after the start of treatment for up to 7 days. Method of measurement: Electrocardiogram.;Examining changes in the patient's breathing status. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: pulse oximeter.;Examination of tumor size. Timepoint: Weekly until 6 months after the end of treatment. Method of measurement: Sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRuhollah Dorostkar
Bagheiat-allah University of Medical Sciences
Outcome results
None listed